## **SUXAMETHONIUM**

Succinylcholine chloride **SYNONYMS BRAND NAME** SUXAMETHONIUM JUNO

**DRUG CLASS** Neuromuscular blocker

**AVAILABILITY** Ampoule contains 100 mg/2 mL of suxamethonium chloride.<sup>1</sup>

Also contains hydrochloric acid. The solution is clear and colourless.<sup>1</sup>

Paralysing agent – causes respiratory arrest. Do not use without adequate sedation. WARNING

Facilities for maintenance of airway and a reversal agent must be readily available.<sup>1,2</sup>

Follow your local guidelines for safe use of neuromuscular blockers. Administration

errors can be fatal.

 $3-5^{1}$ рН

**PREPARATION** Not required

Ampoule: store at 2 to 8 °C. Do not freeze. 1 Stable for 30 days below 25 °C without **STABILITY** 

protection from light. Do not return to the fridge.3

Infusion solution: use within 24 hours.1

**ADMINISTRATION** 

IM injection Suitable for adults and children only when unable to obtain IV access.<sup>1</sup> Inject into a

large muscle preferably the deltoid.4

SUBCUT injection Not recommended

> IV injection For short procedures inject over 10 to 30 seconds.<sup>1</sup>

> > After each dose, flush the line well to avoid re-paralysis during recovery.<sup>1,2</sup>

IV infusion

For prolonged procedures dilute to a concentration of 1–2 mg/mL in sodium chloride

0.9% or glucose 5% and infuse at a rate of 2.5-4.3 mg/minute.1

Titrate to effect. Use an infusion pump.

Flush well or remove the line after the infusion to avoid re-paralysis during

recovery.1,2

IV use for infants and children

Inject diluted or undiluted over 10 to 30 seconds.<sup>1,5</sup>

After each dose, flush the line well to avoid re-paralysis during recovery.<sup>1,2</sup>

Continuous infusion is not recommended.1

See Australasian Neonatal Medicines Formulary (www.anmfonline.org) for use in

newborns.

**COMPATIBILITY** 

Glucose 5%<sup>1</sup>, sodium chloride 0.9%<sup>1</sup>, sodium chloride in glucose solutions<sup>4</sup>,

Hartmann's<sup>4</sup>, Ringer's<sup>4</sup>, Plasma-Lyte 148 via Y-site (at **2 mg/mL** of suxamethonium)<sup>6</sup>

Y-site Giving other drugs via Y-site with neuromuscular blockers is not recommended.

At 2 mg/mL of suxamethonium: palonosetron4

At **8 mg/mL** of suxamethonium: amikacin<sup>7</sup>, aztreonam<sup>7</sup>, buprenorphine<sup>7</sup>, calcium chloride<sup>7</sup>, calcium gluconate<sup>7</sup>, cefazolin<sup>7</sup>, cefotaxime<sup>7</sup>, cefoxitin<sup>7</sup>, ceftazidime<sup>7</sup>, ceftriaxone<sup>7</sup>, ciclosporin<sup>7</sup>, clindamycin<sup>7</sup>, dexamethasone<sup>7</sup>, digoxin<sup>7</sup>, dobutamine<sup>7</sup>, dopamine<sup>7</sup>, ephedrine sulfate<sup>7</sup>, erythromycin<sup>7</sup>, esmolol<sup>7</sup>, fentanyl<sup>7</sup>, fluconazole<sup>7</sup>, furosemide<sup>7</sup>, gentamicin<sup>7</sup>, glyceryl trinitrate<sup>7</sup>, hydrocortisone sodium succinate<sup>7</sup>, labetalol<sup>7</sup>, lidocaine<sup>7</sup>, magnesium sulfate<sup>7</sup>, methylprednisolone sodium succinate<sup>7</sup>, metoclopramide<sup>7</sup>, midazolam<sup>7</sup>, morphine sulfate<sup>7</sup>, noradrenaline (norepinephrine)<sup>7</sup>, ranitidine<sup>7</sup>, sodium nitroprusside<sup>7</sup>, tobramycin<sup>7</sup>, vancomycin<sup>7</sup>, verapamil<sup>7</sup>

At 20 mg/mL of suxamethonium: heparin sodium<sup>4</sup>

continued over the page

**INCOMPATIBILITY** 

Fluids No information

**Drugs** Azathioprine<sup>8</sup>, benzylpenicillin<sup>8</sup>, ganciclovir<sup>8</sup>, phenobarbital<sup>4</sup>, potassium chloride<sup>1</sup>,

quinine<sup>1</sup>, sodium bicarbonate<sup>8</sup>, thiopental sodium<sup>8</sup>

The product information for potassium chloride states incompatibility with

suxamethonium, however compatibility information is available. 7,8 Ask your pharmacy

service for advice.

SPECIAL NOTES Continuous monitoring is required.

Hypersensitivity reactions and cross-sensitivity to other neuromuscular blockers have

been reported.1

## REFERENCES

- Product information. Available from www.tga.gov.au. Accessed 27/12/2022. ISMP Medication Safety Alert, Acute Care. Horsham, PA: Institute for Safe Medication Practices. 2016; 21: 12. Available from www.ismp.org. Accessed 27/12/2022

Accessed 2/712/2022.

3. Medical information. Suxamethonium in-use stability data [letter], Cremorne, Vic: Juno Pharmaceuticals; 12/10/2020.

4. ASHP Injectable drug information 2021. Bethesda, MD: American Society of Health-System Pharmacists; 2021.

5. Paediatric Formulary Committee. BNF for children. London: BMJ group and Pharmaceutical Press; 2022-2023.

6. Medical Information. Plasma-Lyte 148 compatibility summary. Toongabbie, NSW: Baxter; March 2022.

7. Trissel LA, Leissing NC. Trissel's Tables of physical compatibility. Lake Forest IL: Multimatrix; 1996.

8. Succinylcholine chloride. In: IV index. Trissel's 2 clinical pharmaceutics database (parenteral compatibility). Ann Arbour, MI: Merative. Accessed 27/12/2022.

VERSION 9.1